Analytical Data
-
Gene name
CEACAM6
- Application
-
Alternative Names
Carcinoembryonic antigen-related cell adhesion molecule 6; CD66c; NCA
-
Species
Cynomolgus
-
Source
HEK293
-
Tag
C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
XP_014979566
-
Expression Region
Q35-G320
-
Protein Length
Partial
-
Molecular Weight
55-70 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CEACAM6, a member of the carcinoembryonic antigen (CEA) family, is a glycoprotein that plays a significant role in various physiological and pathological processes, including cell adhesion, immune response modulation, and tumor progression. Overexpression of CEACAM6 has been linked to several malignancies, particularly in lung, colorectal, and breast cancers, making it a potential biomarker for cancer diagnosis and prognosis. Research into CEACAM6 recombinant proteins has gained traction due to their potential utility in targeted therapy and vaccine development. The ability to produce CEACAM6 in a recombinant form allows for detailed structural and functional studies, aiding in the understanding of its interactions with other proteins and its role in cancer biology. This research has significant implications, as targeting CEACAM6 could enhance the efficacy of therapeutic strategies, including monoclonal antibodies and immunotherapies. Additionally, understanding the molecular mechanisms underlying CEACAM6 expression and signaling pathways can provide insights into cancer pathogenesis, paving the way for novel interventions that could ultimately improve patient outcomes. Furthermore, CEACAM6's involvement in immune evasion by tumors suggests that modulating its expression or function may restore appropriate immune responses, positioning it as a promising target for combination therapies in oncology. Overall, the study of CEACAM6 recombinant proteins not only enhances our understanding of cancer biology but also holds the promise for advancing therapeutic options in oncology, making it an area of active investigation in contemporary cancer research.
